Loading
A phase 1 trial of ORM-5029 run by Orum Therapeutics USA, Inc., terminated.
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors is a phase 1 interventional study registered as NCT05511844 by Orum Therapeutics USA, Inc., with 25 participants enrolled, started 2022-10-03. Conditions recorded: HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification and HER2 Gene Mutation. Interventions recorded: ORM-5029.
Shares Orum Therapeutics and the tag pipeline.
Shares Orum Therapeutics and the tag pipeline.
Shares Orum Therapeutics and the tag pipeline.
Shares HER2-positive breast cancer and the tag pipeline.
Shares HER2-positive breast cancer and the tag pipeline.
Shares HER2-positive breast cancer and the tag pipeline.
Shares HER2-positive breast cancer and the tag pipeline.
Shares HER2-positive breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/